A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
Noroviruses (NoV) are the leading cause of epidemic acute gastroenteritis in humans worldwide and a safe and effective vaccine is needed. Here, a phase I, double-blind, placebo-controlled clinical trial was performed in 60 healthy adults, 18 to 40 years old. Safety (primary objective) and immunogeni...
Main Authors: | Isabel Leroux-Roels, Cathy Maes, Jasper Joye, Bart Jacobs, Franziska Jarczowski, André Diessner, Yorick Janssens, Gwenn Waerlop, Kirsi Tamminen, Suvi Heinimäki, Vesna Blazevic, Geert Leroux-Roels, Victor Klimyuk, Hiroshi Adachi, Kazuyuki Hiruta, Frank Thieme |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1021500/full |
Similar Items
-
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
by: Gwenn Waerlop, et al.
Published: (2023-06-01) -
Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in <i>Nicotiana benthamiana</i>
by: Maria Malm, et al.
Published: (2019-05-01) -
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
by: Yorick Janssens, et al.
Published: (2022-08-01) -
Norovirus-specific memory T cell responses in adult human donors
by: Maria Malm, et al.
Published: (2016-10-01) -
Human Norovirus Infection in Dogs, Thailand
by: Kamonpan Charoenkul, et al.
Published: (2020-02-01)